1. Defourny, Jean. 2022. Considering gene therapy to protect from X-linked deafness DFNX2 and associated neurodevelopmental disorders. In Ibrain, 8, 431-441. doi:10.1002/ibra.12068. https://pubmed.ncbi.nlm.nih.gov/37786584/
2. Bernardinelli, Emanuele, Huber, Florian, Roesch, Sebastian, Dossena, Silvia. 2023. Clinical and Molecular Aspects Associated with Defects in the Transcription Factor POU3F4: A Review. In Biomedicines, 11, . doi:10.3390/biomedicines11061695. https://pubmed.ncbi.nlm.nih.gov/37371790/
3. Raft, Steven, Coate, Thomas M, Kelley, Matthew W, Crenshaw, E Bryan, Wu, Doris K. 2014. Pou3f4-mediated regulation of ephrin-b2 controls temporal bone development in the mouse. In PloS one, 9, e109043. doi:10.1371/journal.pone.0109043. https://pubmed.ncbi.nlm.nih.gov/25299585/
4. Robert-Moreno, Àlex, Naranjo, Silvia, de la Calle-Mustienes, Elisa, Gómez-Skarmeta, José Luis, Alsina, Berta. 2010. Characterization of new otic enhancers of the pou3f4 gene reveal distinct signaling pathway regulation and spatio-temporal patterns. In PloS one, 5, e15907. doi:10.1371/journal.pone.0015907. https://pubmed.ncbi.nlm.nih.gov/21209840/
5. Song, Mee Hyun, Lee, Kyu-Yup, Choi, Jae Young, Bok, Jinwoong, Kim, Un-Kyung. 2012. Nonsyndromic X-linked hearing loss. In Frontiers in bioscience (Elite edition), 4, 924-33. doi:10.2741/E430. https://pubmed.ncbi.nlm.nih.gov/22201925/